To view the multimedia assets associated with this release, please visit: http://www.multivu.com/mnr/53365-carefusion-unveils-pyxis-automated-medication-dispensing ...

SAN DIEGO, Dec. 7 CareFusion (NYSE: CFN), a leading, global medical device company, today announced six new Pyxis® medication management products at the 44th American Society for Health System ...

SAN DIEGO, June 24, 2013 /PRNewswire/ -- CareFusion Corp. (NYSE: CFN), a leading, global medical technology company, today announced that 14 additional hospitals across the country have adopted the ...

CAMBRIDGE, Mass., March 18, 2021 (GLOBE NEWSWIRE) -- Pyxis Oncology (“Pyxis” or the "Company”) today announced that it has entered into a worldwide license agreement with Pfizer Inc. (NYSE:PFE) for ...

CAMBRIDGE, Mass., March 16, 2023 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company focused on developing next-generation therapeutics to target difficult-to-treat ...

KSA, 12 May 2013 CareFusion, a leading global medical technology company, announced it will highlight its medication safety solutions at Saudi Health, being held at the Riyadh International Convention ...

Pyxis Oncology has plenty to do with three antibody-drug conjugates in the pipeline, so the upstart biotech has formed a new joint venture called Kyma Therapeutics with Alloy Therapeutics to develop ...

When patients begin receiving care at St. Luke's Same Day Surgery Center in April, they'll receive medications through a computerized pharmacy system that's been in use throughout St. Luke's Regional ...

Stephens has initiated coverage on Pyxis Oncology Inc (NASDAQ:PYXS), highlighting the company’s technology platform aimed at developing next-gen antibody-drug conjugates (ADCs) with enhanced potency, ...

Pyxis Oncology is slimming down after a tough start to life on public markets, pausing work on two assets and stopping development of a third altogether to focus its cash on getting its lead programs ...

On Wednesday, Pyxis Oncology, Inc. (NASDAQ:PYXS) released preliminary data from the ongoing Phase 1 clinical dose escalation study evaluating PYX-201 in multiple solid tumors. Among evaluable Head and ...